跳至主要内容
临床试验/ISRCTN45536692
ISRCTN45536692已完成未知

A double-blind randomised controlled trial (RCT) to assess the feasibility of giving Zoledronic acid alongside chemotherapy in patients with mesothelioma to design a larger trial to assess the efficacy of Zoledronic acid alongside first line chemotherapy

orth Bristol NHS Trust0 个研究点目标入组 22 人开始时间: 2016年8月9日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
22

研究概览

简要总结

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Histologically confirmed diagnosis of MPM
  • 2. WHO performance status 0-1
  • 3. Eligible for first line chemotherapy treatment Measurable disease on CT as per modified RECIST criteria (tumour thickness > 5mm)
  • 4. Ability to give informed consent
  • 5. Aged 18 years and over

排除标准

  • 1. Not fit for chemotherapy due to performance status or other comorbidities Previous chemotherapy for MPM
  • 2. IV bisphosphonates in the 3 months preceding randomisation
  • 3. Significant renal disease (eGFR < 30ml/min in the last 4 weeks)
  • 4. Hypocalcaemia (current hypocalcaemia on treatment, evidence of hypocalcaemia on most recent blood tests - should be within last 6 weeks)
  • 5. Pregnancy or lactation Age
  • 6. Age < 18 years
  • 7. Known allergy to bisphosphonates or excipients of its preparation
  • 8. Severe untreated dental caries
  • 9. Concomitant participation in another drug trial for mesothelioma

研究者

发起方
orth Bristol NHS Trust

相似试验